Heme Iron Polypeptide (HIP)

Evidence Level
Limited
2 Clinical Trials
5 Documented Benefits
2/5 Evidence Score

Heme iron polypeptide (HIP, brand: Proferrin) is an animal blood product. Proferrin is refined from bovine hemoglobin, enzymatically digested so the iron stays inside its heme ring attached to a short peptide. It is not vegetarian or vegan, and because blood is prohibited under both kashrut and halal rules it is also off limits to observant Jewish and Muslim readers. In head to head randomized trials it has mostly failed to beat cheap ferrous salts. A 2025 trial in 208 anemic infants found no difference from ferrous sulfate in hemoglobin or ferritin, a trial in women after gastric bypass was stopped early because ferrous sulfate corrected the deficiency while heme iron moved no iron marker, and a peritoneal dialysis trial found no benefit at seven times the cost. Pooling 13 trials, the only advantages that emerged were fewer reported side effects and a hemoglobin gain in children, both graded very low certainty.

Studied Dose Trial doses ran from 10 to 94.5 mg/day of heme iron; Proferrin supplies 10.5 mg per tablet; the folic acid in Forte can mask a vitamin B12 deficiency, so check B12 first.
Active Compound Heme iron polypeptide, an animal blood product. Proferrin is refined from bovine hemoglobin; other heme iron ingredients use porcine or fish blood, and the species is not always stated on the label.

Benefits

Absorbed by a Different Route Than Iron Salts

Heme iron enters the duodenal cell with the iron still inside its porphyrin ring rather than as free ferrous iron, so the phytates in grains and the polyphenols in tea and coffee that block ferrous salts have little effect on it. The carrier was originally named HCP1 (heme carrier protein 1), but the same gene product was shown in 2006 to work mainly as the intestinal proton coupled folate transporter, and the human heme importer has still not been identified. Calcium is not bypassed: in a study of 126 people, 165 mg of calcium given as milk, cheese or calcium chloride significantly reduced heme iron absorption as well as non-heme iron absorption.

Larger Short Term Serum Iron Rise When Taken with Food

The direct comparison is a 14 person crossover published in Nutrition Research in 2000: 20 mg of iron as heme iron polypeptide taken with breakfast produced a larger rise in serum iron over 6 hours than 20 mg as ferrous fumarate (p<0.03). That study is small, it has never been independently replicated, and the journal it appeared in is not indexed in MEDLINE. The 2025 infant trial found the same pattern on blood markers, with 48 percent higher serum iron and 52 percent higher transferrin saturation on heme iron. That short term marker advantage did not carry through to the outcomes that decide whether anemia gets better: hemoglobin and ferritin were no different from ferrous sulfate.

Fewer Reported Side Effects, on Weak Evidence

Pooling 13 randomized trials, people given heme iron reported 38 percent fewer total side effects than people given non-heme iron (RR 0.62, 95 percent CI 0.40 to 0.96). The reviewers graded that result very low certainty and noted that most of the trials gave heme iron in low doses combined with non-heme iron, often at a lower total iron dose, and a lower iron dose on its own reduces gut symptoms. In the largest single trial, 208 anemic infants on 10 mg/day, adverse events occurred at the same rate on heme iron and on ferrous sulfate.

Less Dependent on Stomach Acid, But Not Calcium Proof

Heme iron does not have to be freed from a salt by stomach acid, so acid suppressing drugs are expected to interfere with it less than they do with ferrous sulfate. That is a mechanistic expectation: no trial has compared heme iron with a ferrous salt in people taking proton pump inhibitors. Coffee and tea polyphenols do have little effect on it. Calcium is the real exception and should not be lumped in with them, because calcium significantly reduces heme iron absorption in humans.

Where It Has Actually Been Tested

Randomized testing of heme iron polypeptide has been done in peritoneal dialysis patients, in non-dialysis chronic kidney disease, in women after Roux-en-Y gastric bypass, and in anemic infants. The gastric bypass trial is the one people cite this product for, and it went the other way: the researchers stopped it early because ferrous sulfate raised hemoglobin from 10.8 to 13.0 g/dL and ferritin from 4.9 to 15.5 ug/L while heme iron changed none of the iron markers. It has never been tested in inflammatory bowel disease, and it has never been tested in people taking proton pump inhibitors.

Mechanism of action

1

Intact Heme Uptake, Then Release Inside the Cell

Heme is taken up intact across the apical membrane of the duodenal cell, and once inside, heme oxygenase 1 opens the porphyrin ring and frees the iron, which then leaves the cell through ferroportin exactly as iron from a ferrous salt does. The transporter that carries heme in has not been identified in humans. The candidate proposed in 2005 and called HCP1 turned out to be the intestinal proton coupled folate transporter, so any claim built on a named heme transporter is running ahead of the evidence.

2

Bypass of Iron Absorption Inhibitors

Phytate from grains and legumes, polyphenols from tea and coffee, and oxalates all cut absorption of non-heme iron. Because heme reaches the gut wall with the iron still locked in its ring, those three have much less grip on it. Calcium does not belong on that list: it reduces heme iron absorption too, which points to the block being at the transfer step inside the cell rather than in the gut lumen.

3

Animal Source Polypeptide Matrix

HIP is made by enzymatically digesting hemoglobin from slaughterhouse blood, leaving heme still attached to short peptides. Proferrin is refined from bovine blood; other heme iron ingredients are made from porcine blood, and heme iron has also been produced from fish blood. It is chemically the same form of iron found in red meat, which is why the marketing borrows the absorption figures for dietary heme. Those figures come from meat in a meal, not from this tablet.

4

Reduced Mucosal Irritation

Less free ferrous iron sitting in the gut lumen should mean less oxidative irritation of the gut lining, which is the proposed reason for better tolerability. The human evidence for that is thin: pooled trials show a 38 percent reduction in reported side effects at very low certainty, while the largest single trial found no difference in adverse events at all.

Clinical trials

1
Heme Iron vs Ferrous Sulfate in Anemic Infants: Randomized, 84 Days
PubMed

Bah M, Verhoef H, Okoh E, et al. Am J Clin Nutr 2025;122(4):997-1005. PMID 40803493. Randomized, 84 days of directly observed daily supplementation with 10 mg elemental iron as heme iron polypeptide or as ferrous sulfate. Adherence about 90 percent.

208 anemic infants aged 6 to 12 months in The Gambia (hemoglobin 7.0 to under 11.0 g/dL).

Hemoglobin and ferritin improved in both groups by day 84 with no difference between treatments, and the authors concluded there is no benefit of heme iron on those endpoints. Anemia prevalence fell from 83.7 to 46.2 percent on ferrous sulfate and from 84.6 to 47.1 percent on heme iron. Heme iron did produce higher serum iron (by 48.4 percent) and higher transferrin saturation (by 52.3 percent). Adverse events occurred at the same rate in both groups.

2
Heme Iron vs Ferrous Sulfate After Gastric Bypass: Randomized, Stopped Early
PubMed

Mischler RA, Armah SM, Craig BA, et al. Obes Surg 2018;28(2):369-377. PMID 28779269. Randomized, single blind, 8 weeks of ferrous sulfate 195 mg/day or heme iron polypeptide 31.5 to 94.5 mg/day. Compliance above 94 percent. The trial was stopped early.

14 iron deficient women an average of 6.9 years after Roux-en-Y gastric bypass (6 on ferrous sulfate, 8 on heme iron).

On ferrous sulfate, hemoglobin rose from 10.8 to 13.0 g/dL, ferritin from 4.9 to 15.5 ug/L and soluble transferrin receptor fell from 2111 to 1270 ug/L, all p<0.0001. On heme iron polypeptide, no iron status marker changed. The investigators stopped the trial early because of the size of the difference and concluded that ferrous sulfate, but not heme iron, corrected iron deficiency after this surgery. With 14 participants the trial is small, and it does not tell you how heme iron performs in people with normal gut anatomy.

Side effects and drug interactions

Common Potential side effects

Accidental overdose of iron containing products is a leading cause of fatal poisoning in children under 6. Keep it out of reach and call a doctor or poison control immediately if a child swallows any.
Constipation, nausea, stomach pain and dark stools can still happen. In the largest trial, adverse events occurred at the same rate on heme iron as on ferrous sulfate.
Do not take iron without a blood test showing you need it. In hereditary hemochromatosis, other iron overload states, or unexplained high ferritin, iron supplements cause harm, and heme iron is a poor choice there because it is still absorbed by people whose iron stores are already full.
Cost: in the peritoneal dialysis trial heme iron polypeptide cost seven times as much as ferrous sulphate and produced no measured benefit.
It is an animal blood product, not merely animal derived. Proferrin is refined from bovine hemoglobin and other heme iron ingredients use porcine blood, so it is unsuitable for vegetarians and vegans. Consuming blood is prohibited under both kashrut and halal rules regardless of the animal, so it is also unsuitable for observant Jewish and Muslim readers. Manufacturers do not always name the source species on the label.

Important Drug interactions

Fewer interactions are expected than with ferrous salts, but almost none of this has been tested head to head in people actually taking those drugs.
Calcium: this is not an advantage. In a study of 126 people, 165 mg of calcium given as milk, cheese or calcium chloride significantly reduced heme iron absorption as well as non-heme iron absorption. Separate calcium supplements and dairy from the dose.
PPIs, H2 blockers and antacids: heme iron does not need stomach acid to be freed from a salt, so less interference is expected. No trial has measured this in people on acid suppression.
Coffee/tea tannins — do not meaningfully reduce heme iron absorption.
Tetracyclines/quinolones — not chelated by heme; minimal interaction (advantage).
Levothyroxine — minimal interaction (advantage).
Vitamin C — enhances ferrous salt absorption but minimal effect on heme iron (already well-absorbed).
Practical point: heme iron can be taken with meals, coffee or tea without the absorption losses that hit ferrous salts. Calcium and dairy are the exception and do reduce it.

Frequently asked questions about Heme Iron Polypeptide (HIP)

What is heme iron polypeptide?

Heme iron polypeptide is iron in the heme form (derived from animal hemoglobin), the same chemical form of iron found in meat. It is made by digesting slaughterhouse blood, so it is not vegetarian, not vegan, and not permitted under kosher or halal rules. It is absorbed by a different route than iron salts, so phytate, tea and coffee interfere with it less, though calcium still does.

Is heme iron better absorbed than regular iron?

It is absorbed more efficiently gram for gram, and coffee and tea interfere with it less, though calcium still reduces it. What that has not translated into is better results. In randomized trials against ferrous sulfate, heme iron did no better on hemoglobin or ferritin in anemic infants, did nothing at all in women after gastric bypass, and gave no advantage in dialysis patients at seven times the price. Its case rests on tolerability, and even that finding is graded very low certainty.

How much heme iron polypeptide should I take?

Proferrin ES is labeled at 1 to 3 tablets a day, which is 10.5 to 31.5 mg of heme iron; published trials have used 10 to about 95 mg a day. Only supplement iron for a confirmed deficiency, ideally under medical guidance.

Does heme iron cause fewer side effects?

Probably a little, and the evidence is weak. Across 13 randomized trials, total side effects were 38 percent lower with heme iron (RR 0.62), but the reviewers rated that very low certainty and most of those trials gave heme iron in low doses combined with non-heme iron, at a lower total iron dose, which reduces gut symptoms by itself. The largest single trial found no difference in adverse events at all. It is not suitable for vegetarians or vegans, since it comes from animal blood.

What is Heme Iron Polypeptide used for?

Heme Iron Polypeptide is researched primarily for Energy. Heme iron enters the duodenal cell with the iron still inside its porphyrin ring rather than as free ferrous iron, so the phytates in grains and the polyphenols in tea and coffee that block ferrous salts have little effect on it.

What is the recommended dosage of Heme Iron Polypeptide?

The clinically studied dose is Trial doses ran from 10 to 94.5 mg/day of heme iron; Proferrin supplies 10.5 mg per tablet; the folic acid in Forte can mask a vitamin B12 deficiency, so check B12 first. Always follow the product label and check with a healthcare provider for personal advice.

Is Heme Iron Polypeptide safe, and does it have side effects?

For most healthy adults, Heme Iron Polypeptide is well tolerated at studied doses. Reported effects can include: Accidental overdose of iron containing products is a leading cause of fatal poisoning in children under 6. Keep it out of reach and call a doctor or poison control immediately if a child swallows any. Constipation, nausea, stomach pain and dark stools can still happen. It may also interact with some medications. Heme Iron Polypeptide is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does Heme Iron Polypeptide interact with any medications?

Possible interactions include: Fewer interactions are expected than with ferrous salts, but almost none of this has been tested head to head in people actually taking those drugs. Calcium: this is not an advantage. If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for Heme Iron Polypeptide?

NutraSmarts rates the evidence for Heme Iron Polypeptide as Limited (2 out of 5). It is backed by 2 clinical trials and 11 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(11 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Bah M, Verhoef H, Okoh E, et al. Heme iron compared with ferrous iron salts to treat iron deficiency anemia in Gambian children: a randomized controlled trial. Am J Clin Nutr. 2025;122(4):997-1005..PubMedUsed to support: In 208 anemic Gambian infants aged 6 to 12 months randomly assigned to 84 days of directly observed 10 mg elemental iron a day as heme iron polypeptide or as ferrous sulfate, hemoglobin and ferritin improved in both groups with no difference between treatments, and the authors concluded there is no benefit of heme iron on those endpoints. Anemia prevalence fell from 83.7 to 46.2 percent on ferrous sulfate and from 84.6 to 47.1 percent on heme iron. Heme iron produced higher serum iron (by 48.4 percent) and higher transferrin saturation (by 52.3 percent), and adverse events occurred at the same rate in both groups.
  2. Hallberg L, Brune M, Erlandsson M, Sandberg AS, Rossander-Hulten L. Calcium: effect of different amounts on nonheme- and heme-iron absorption in humans. Am J Clin Nutr. 1991;53(1):112-119..PubMedUsed to support: In 126 human subjects, calcium reduced iron absorption in a dose related way, and 165 mg of calcium given as milk, cheese or calcium chloride significantly reduced heme iron absorption as well as non-heme iron absorption. The authors attribute the effect to the mucosal transfer step, which is shared by both forms of iron.
  3. Frykman E, Bystrom M, Jansson U, Edberg A, Hansen T. Side effects of iron supplements in blood donors: superior tolerance of heme iron. J Lab Clin Med. 1994;123(4):561-564..PubMedUsed to support: In a double blind trial in regular blood donors, a combined heme plus non-heme iron tablet supplying 18 mg iron a day caused significantly less constipation and fewer total side effects than a non-heme iron tablet supplying 60 mg a day, while restoring ferritin and hemoglobin equally well. The heme arm delivered roughly a third of the iron, so dose and iron form are confounded in this comparison.
  4. Nissenson AR, Berns JS, Sakiewicz P, Ghaddar S, Moore GM, Schleicher RB, Seligman PA. Clinical evaluation of heme iron polypeptide: sustaining a response to rHuEPO in hemodialysis patients. Am J Kidney Dis. 2003;42(2):325-330..PubMedUsed to support: An open, 6 month study in 37 hemodialysis patients switched from intravenous iron to oral heme iron polypeptide. Transferrin saturation and hematocrit were maintained, but average serum ferritin fell significantly from month 4 onward, and 11 percent of patients dropped out for insufficient iron supplementation or intolerance. There was no control group.
  5. Qiu A, Jansen M, Sakaris A, Min SH, Chattopadhyay S, Tsai E, Sandoval C, Zhao R, Akabas MH, Goldman ID. Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption. Cell. 2006;127(5):917-928..PubMedUsed to support: The gene product reported in 2005 as heme carrier protein 1 (HCP1) was shown to function mainly as a proton coupled, high affinity intestinal folate transporter, and a loss of function mutation in it causes hereditary folate malabsorption. The authors renamed it PCFT/HCP1.
  6. Barraclough KA, Brown F, Hawley CM, Leary D, Noble E, Campbell SB, Isbel NM, Mudge DW, van Eps CL, Johnson DW. A randomized controlled trial of oral heme iron polypeptide versus oral iron supplementation for the treatment of anaemia in peritoneal dialysis patients: HEMATOCRIT trial. Nephrol Dial Transplant. 2012;27(11):4146-4153..PubMedUsed to support: In 62 peritoneal dialysis patients randomized for 6 months, transferrin saturation was 22 percent on heme iron polypeptide versus 20 percent on ferrous sulphate (p=0.65). Serum ferritin was significantly lower on heme iron (p=0.003) and heme iron cost seven times as much. The authors concluded it showed no clear safety or efficacy benefit in these patients.
  7. Nagaraju SP, Cohn A, Akbari A, Davis JL, Zimmerman DL. Heme iron polypeptide for the treatment of iron deficiency anemia in non-dialysis chronic kidney disease patients: a randomized controlled trial. BMC Nephrol. 2013;14:64..PubMedUsed to support: 40 non-dialysis chronic kidney disease patients were randomized to heme iron polypeptide 11 mg three times daily by mouth or intravenous iron sucrose 200 mg monthly for 6 months. Hemoglobin at 6 months was 117 g/L on heme iron and 113 g/L on iron sucrose (p=0.37), but serum ferritin was much lower on heme iron (85.5 versus 244 ug/L, p=0.004).
  8. Dull RB, Davis E. Heme iron polypeptide for the management of anaemia of chronic kidney disease. J Clin Pharm Ther. 2015;40(4):386-390..PubMedUsed to support: A review of three clinical studies of heme iron polypeptide in chronic kidney disease, covering 161 patients in total. Heme iron was consistently associated with lower ferritin than conventional iron, and its effects on hemoglobin, hematocrit, transferrin saturation, erythropoietin dose and adverse effects were similar to oral non-heme and intravenous iron. The authors concluded it does not appear to confer benefit over traditional iron supplementation and is more expensive.
  9. Mischler RA, Armah SM, Craig BA, Rosen AD, Banerjee A, Selzer DJ, Choi JN, Gletsu-Miller N. Comparison of Oral Iron Supplement Formulations for Normalization of Iron Status Following Roux-EN-y Gastric Bypass Surgery: a Randomized Trial. Obes Surg. 2018;28(2):369-377..PubMedUsed to support: In 14 iron deficient women after Roux-en-Y gastric bypass, 8 weeks of ferrous sulfate raised hemoglobin from 10.8 to 13.0 g/dL and ferritin from 4.9 to 15.5 ug/L (both p<0.0001), while heme iron polypeptide at 31.5 to 94.5 mg/day changed no iron status marker. The trial was stopped early because of the size of the difference.
  10. Shahinfar H, Jayedi A, Shab-Bidar S. Dietary iron intake and the risk of type 2 diabetes: a systematic review and dose-response meta-analysis of prospective cohort studies. Eur J Nutr. 2022;61(5):2279-2296..PubMedUsed to support: Across 11 prospective cohorts covering 323,788 people and 28,837 cases, higher dietary heme iron intake was associated with a 20 percent higher risk of type 2 diabetes (95 percent CI 1.07 to 1.35), rising 16 percent per additional 1 mg a day, graded moderate certainty. No association was seen for total, non-heme or supplemental iron. These are observational data on heme iron eaten as meat, not on a heme iron tablet, which has never been studied for this outcome.
  11. Gallo Ruelas M, Alvarado-Gamarra G, Aramburu A, Dolores-Maldonado G, Cueva K, Rojas-Limache G, Diaz-Parra CDP, Lanata CF. A comparative analysis of heme vs non-heme iron administration: a systematic review and meta-analysis of randomized controlled trials. Eur J Nutr. 2024;64(1):51..PubMedUsed to support: Across 13 randomized trials, heme iron gave no significant advantage over non-heme iron on any iron status indicator except in children with iron deficiency or anemia, where hemoglobin rose 1.06 g/dL more (95 percent CI 0.34 to 1.78). Total side effects were 38 percent lower with heme iron (RR 0.62, 95 percent CI 0.40 to 0.96). Every estimate was graded very low certainty, and most of the trials gave heme iron in low doses combined with non-heme iron.